The clinical and genetic aspects of six individuals with GH1 variants and isolated growth hormone deficiency type II
Frontiers in Endocrinology · 2024
DOI: 10.3389/fendo.2024.1363050 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Endocrinology, 2024. Verfasst von Xiaozhen Huang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Genetics and Metabolism, Fuzhou Children's Hospital of Fujian Medical University, Fuzhou, Fujian, ;China. Hauptthemen laut MEDLINE: Dwarfism, Pituitary, Human Growth Hormone, Pedigree. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Isolated growth hormone deficiency type II (IGHD II) is an autosomal dominant disorder characterized by a GH1 gene variant resulting in a significant reduction in growth hormone (GH) secretion and a subsequent decrease of plasma insulin-like growth factor 1 (IGF-1) levels and eventual growth impairment.
Objective
This study aimed to identify causative variants in six Chinese families with IGHD II, exploring both clinical and genetic characteristics.
Methods
Detailed clinical data, including clinical presentations, physical charateristics, medical and family histories, as well as genetic test results, were systematically examined.
Results
Six children, comprising four males and two females, with a mean age of 4.64 ± 1.15 years, exhibited short stature with a mean height of -3.95 ± 1.41 SDS. Four of them had a family history of short stature, while one patient presented with pulmonary hypertension. All children demonstrated GH deficiency in growth hormone stimulation tests (mean peak GH value: 2.83 ± 2.46 ng/mL). Exome sequencing for the six patients and targeted gene sequencing for their family members revealed heterozygous variants in the GH1 gene, including Exon2-5del, c.334T>C, c.291 + 1G>A, c.291 + 2T>A, 1.5 kb deletion, and 1.7 kb deletion, with four variants being novel. Four patients underwent human recombinant growth hormone (rhGH) replacement therapy, initiating treatment at a mean age of 4.6 ± 0.7 years. The mean height increase in patients was 1.21 ± 0.3 SDS in the first six months of treatment and 1.79 ± 0.15 SDS in the first year.
Conclusion
Our findings contribute to expanding the genotypic and phenotypic spectra of individuals with IGHD II.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Genetics and Metabolism, Fuzhou Children's Hospital of Fujian Medical University, Fuzhou, Fujian, ;China.
Zitieren
APA
Huang, X., Chen, H., Shangguan, H., Wu, W., Ai, Z., Chen, Z., & Chen, R. (2024). The clinical and genetic aspects of six individuals with GH1 variants and isolated growth hormone deficiency type II. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2024.1363050
Vancouver
Huang X, Chen H, Shangguan H, Wu W, Ai Z, Chen Z, et al. The clinical and genetic aspects of six individuals with GH1 variants and isolated growth hormone deficiency type II. Frontiers in Endocrinology. 2024. doi:10.3389/fendo.2024.1363050
BibTeX
@article{Huang2024,
author = {Huang, Xiaozhen and Chen, Hong and Shangguan, Huakun and Wu, Wenyong and Ai, Zhuanzhuan and Chen, Zhifeng and Chen, Ruimin},
title = {The clinical and genetic aspects of six individuals with GH1 variants and isolated growth hormone deficiency type II},
journal = {Frontiers in Endocrinology},
year = {2024},
doi = {10.3389/fendo.2024.1363050}
}
EUVIMED